A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective?

Nabi‐Afjadi, Mohsen; Mohebi, Fatemeh; Zalpoor, Hamidreza; Aziziyan, Fatemeh; Akbari, Abdullatif; Moradi-Sardareh, Hemen; Bahreini, Elham; Moeini, Amir Mansour; Effatpanah, Hossein

doi:10.1007/s10787-022-01129-1

Cited by 12 publications

(6 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, as long as more reliable data emerge from randomized trials with sufficient size, dose, and duration, healthcare providers should refrain from prescribing ivermectin to treat or prevent COVID-19. Also, combined treatment of ivermectin with other drugs may minimize adverse effects and demonstrate its therapeutic efficacy in the treatment of COVID-19, as we suggested in our previous study [25]. Thus, we hope that this hypothesis will encourage further investigations and consideration of the possible prophylactic roles of ivermectin against Omicron and future variants of SARS-CoV-2 to save the lives of many people and prevent hospitalization and morbidity.…”

Section: Countrymentioning

confidence: 61%

See 2 more Smart Citations

Keeping Ready against Omicron and Future Variants: Can Ivermectin Prophylactic Effects Improve the Vaccination Effects against COVID-19?

Zalpoor

Nabi‐Afjadi

Aziziyan

et al. 2023

Arch Pharmacol Ther

View full text Add to dashboard Cite

The standard treatment options for Coronavirus disease 2019 (COVID-19) remain challenging despite community vaccinations and reduced mortality. As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus continues to evolve and new strains emerge, diversity in the use of existing antiviral drugs has become a crucial therapeutic tool in combating the COVID-19 epidemic. Many types of infectious diseases, including DNA and RNA viruses, have traditionally been treated with ivermectin, a broad-spectrum anti-parasitic, and anti-viral drug. In spite of this, the effectiveness of ivermectin as a treatment for SARS-CoV-2 is still controversial, based on currently available data. The aim of this study was to provide comprehensive information on ivermectin, including its safety and efficacy. We hypothesized that ivermectin prophylactic effects may enhance vaccine effectiveness against SARS-CoV-2 infection in this study. Also, the combination of ivermectin with other drugs to reduce its adverse effects could be beneficial and we suggest that it can be evaluated in future studies.

show abstract

Section: Countrymentioning

confidence: 61%

“…Table 2. Clinical trials investigated the anti-COVID-19 effects of Ivermectin [25]. Also, in simultaneous use of ivermectin, some drugs have been proposed to reduce its side effects.…”

Section: Role As An Ionophorementioning

confidence: 99%

See 1 more Smart Citation

Keeping Ready against Omicron and Future Variants: Can Ivermectin Prophylactic Effects Improve the Vaccination Effects against COVID-19?

Zalpoor

Nabi‐Afjadi

Aziziyan

et al. 2023

Arch Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Recent research revealed that IVM may inhibit the lipopolysaccharide-induced production of inflammatory cytokines via the inhibition of importin α/β, a pathway of protein transport into the nucleus. It is also reported that ivermectin targets host inflammatory pathways like nuclear factor kappa-lightchain-enhancer of activated B cells (NF-κB), Akt kinase/mammalian target of rapamycin (AKT/mTOR), and signal transducer and activator of transcription 3 (STAT3) [15][16][17][18][19].…”

Section: Introductionmentioning

confidence: 99%

Impact of Ivermectin on the Gut Microbial Ecosystem

Liu,

Mahalak,

Bobokalonov

et al. 2023

IJMS

View full text Add to dashboard Cite

Ivermectin is a an anti-helminthic that is critical globally for both human and veterinary care. To the best of our knowledge, information available regarding the influence of ivermectin (IVM) on the gut microbiota has only been collected from diseased donors, who were treated with IVM alone or in combination with other medicines. Results thus obtained were influenced by multiple elements beyond IVM, such as disease, and other medical treatments. The research presented here investigated the impact of IVM on the gut microbial structure established in a Triple-SHIME® (simulator of the human intestinal microbial ecosystem), using fecal material from three healthy adults. The microbial communities were grown using three different culture media: standard SHIME media and SHIME media with either soluble or insoluble fiber added (control, SF, ISF). IVM introduced minor and temporary changes to the gut microbial community in terms of composition and metabolite production, as revealed by 16S rRNA amplicon sequencing analysis, flow cytometry, and GC-MS. Thus, it was concluded that IVM is not expected to induce dysbiosis or yield adverse effects if administered to healthy adults. In addition, the donor’s starting community influences the relationship between IVM and the gut microbiome, and the soluble fiber component in feed could protect the gut microbiota from IVM; an increase in short-chain fatty acid production was predicted by PICRUSt2 and detected with IVM treatment.

show abstract

“…

Dear Editor, Nowadays, a number of studies suggest that patients with primary diseases such as multiple cancers are more susceptible to severe Coronavirus disease-2019 (COVID-19) and mortality [1][2][3]. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for COVID-19 infection and has a variety of cell and organ targets [4].

…”

mentioning

confidence: 99%

CD147 and cyclophilin A: a promising potential targeted therapy for COVID-19 and associated cancer progression and chemo-resistance

Bakhtiyari

Aghasi

Banihashemi

et al. 2023

Infect Agents Cancer

Self Cite

View full text Add to dashboard Cite

Coronavirus disease-2019 (COVID-19), as a worldwide serious issue has been shown to lead to progression and poor outcomes in cancer patients. The underlying mechanisms for SARS-CoV-2 infection’s adverse effects on cancer patients have not been fully understood. We hypothesized that CD147 and Cyclophilin A (CyPA) not only can play a significant role in infection severity but also can contribute to cancer progression and chemotherapy resistance in cancer patients with COVID-19. In addition, we hypothesized that the expression of both CD147 and CyPA could be increased by Hypoxia-inducible Factor-1 alpha (HIF-1α) activation during hypoxic conditions that occurred during COVID-19. Therefore, this evidence can open a new window in the management of cancer patients during the pandemic and therapeutic approaches targeting CD147 and CyPA could be a potentially promising therapeutic approach for such patients.

show abstract

A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective?

Cited by 12 publications

References 122 publications

Keeping Ready against Omicron and Future Variants: Can Ivermectin Prophylactic Effects Improve the Vaccination Effects against COVID-19?

Keeping Ready against Omicron and Future Variants: Can Ivermectin Prophylactic Effects Improve the Vaccination Effects against COVID-19?

Impact of Ivermectin on the Gut Microbial Ecosystem

CD147 and cyclophilin A: a promising potential targeted therapy for COVID-19 and associated cancer progression and chemo-resistance

Contact Info

Product

Resources

About